| HOME >> BIOLOGY >> TECHNOLOGY |
Advanced subsidies 1,077 329
Other taxes payable 4,060 2,343
Other current liabilities 1,233 1,428
Total current liabilities 45,572 30,594
Non-current liabilities:
Long-term debt, excluding current portion 4,107 5,763
Advanced subsidies 1,529 1,027
Convertible notes 40,988 --
Deferred tax liabilities 181 129
Total non-current liabilities 46,805 6,919
Total liabilities 92,377 37,513
Mezzanine equity: -- 49,106
Shareholders' equity (deficit):
Ordinary shares (Note 1), ($0.02 par
value, 5,002,550,000 authorized
249,060,000 and 492,226,776 issued
and outstanding as of December 31,
2006 and 2007, respectively) 9,845 4,981
Additional paid-in capital 291,020 33,075
Accumulated deficit (57,302) (40,173)
Accumulated other comprehensive income 7,835 1,549
Treasury stock -- (360)
Total shareholders' equity (deficit) 251,398 (928)
Total liabilities, mezzanine equity and
shareholders' equity (deficit) 343,775 85,691
Note 1: Eight (8) ordinary shares are equal to one (1) ADS
WUXI PHARMATECH (CAYMAN) INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands of US d
'/>"/>
| SOURCE WuXi PharmaTech (Cayman) Inc. Copyright©2008 PR Newswire. All rights reserved |